Mersana Therapeutics alternatives
9 products to explore · 2026
Your shortlist, at a glance.
Read the comparisons ↓Check each product’s website for current pricing and features. A verified badge indicates a verified listing, not a ranking.
About Mersana Therapeutics and its alternatives
Users searching for Mersana Therapeutics alternatives are typically exploring other developers of antibody-drug conjugates or clinical-stage oncology programs after Mersana's acquisition by Day One Biopharmaceuticals. They want companies still independently advancing ADCs with differentiated payloads, novel linkers, or tumor-specific targeting for solid tumors and hematologic cancers. Common priorities include comparing pipeline maturity, clinical data readouts, partnership structures, and remaining standalone status versus programs now integrated into larger portfolios like Servier. Searchers often evaluate options that offer similar first-in-class potential without the same acquisition history, seeking either public biotech peers or established pharma ADC platforms that continue to run independent trials. This page highlights well-known alternatives with transparent comparisons on development focus, stage, and strategic positioning relative to the former Mersana pipeline.
Explore the alternatives
- V
1.Valink Therapeutics
Healthcare & MedicalDiscovering bispecific antibody drug-conjugates (BsADC) against cancer
2.Adcetris
Healthcare & MedicalOncology therapy developed through rigorous clinical research
3.Blenrep
Healthcare & MedicalGSK oncology medicine advancing targeted antibody-drug conjugate therapy for cancer
- F
4.Farxiga
Healthcare & MedicalScience-led biopharmaceutical medicine for cardiovascular, renal and metabolic conditions.
5.Gilead Sciences (Kite Pharma)
Healthcare & MedicalBiopharma leader advancing therapies in virology, oncology and inflammation
- I
6.ImmunoGen
Healthcare & MedicalImmunoGen
7.Roche Ventana
Healthcare & MedicalDoing now what patients need next
8.Sutro Biopharma
Healthcare & MedicalClinical-stage biotech advancing next-generation ADCs via cell-free XpressCF platform
9.Zymeworks
Healthcare & MedicalRoyalty-driven biotech developing antibody medicines for hard-to-treat cancers
See more comparisons in Healthcare & Medical alternatives.
Questions about Mersana Therapeutics alternatives
What are the strongest clinical-stage ADC companies still independent after the Mersana acquisition?
Several public biotechs continue standalone ADC development with differentiated platforms; key examples include companies running phase 2/3 solid tumor trials using novel payloads or site-specific conjugation that were never acquired by larger oncology groups.
How does Emi-Le from the former Mersana pipeline compare to other first-in-class ADCs in development?
Emi-Le targets a distinct antigen with a differentiated mechanism; competing first-in-class ADCs often focus on different tumor markers or use alternative payload classes, leading to varying safety and efficacy profiles across indications.
Are there public companies developing ADCs for both adult and pediatric cancers like the Day One post-acquisition strategy?
Most ADC developers concentrate on adult solid tumors; only a small subset run dedicated pediatric programs, making cross-age pipelines relatively rare outside large pharma or specialized oncology groups.
Which ADC platforms offer similar payload-linker technology to Mersana's historical approach?
Platforms using auristatin or maytansinoid derivatives with cleavable or non-cleavable linkers provide the closest technical parallels, though many have shifted toward topoisomerase or other novel payloads in recent trials.
What alternatives exist for investors seeking pure-play ADC exposure post-Mersana acquisition?
Investors can review other clinical-stage ADC companies with active pipelines and upcoming data catalysts that remain independent or have different partnership models than the Servier integration.
How do ongoing trials from former Mersana assets compare in timeline to competing ADC readouts?
Day One's integrated timeline now includes Emi-Le alongside existing assets; competing programs often publish phase 2 data on different schedules depending on indication and regulatory path.